Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 33

1.

Bremelanotide (Vyleesi) for hypoactive sexual desire disorder.

[No authors listed]

Med Lett Drugs Ther. 2019 Jul 29;61(1577):114-116. Review. No abstract available.

PMID:
31381550
2.

Expert opinion on existing and developing drugs to treat female sexual dysfunction.

Miller MK, Smith JR, Norman JJ, Clayton AH.

Expert Opin Emerg Drugs. 2018 Sep;23(3):223-230. doi: 10.1080/14728214.2018.1527901. Epub 2018 Oct 11. Review.

PMID:
30251897
3.

Female Sexual Dysfunction and the Placebo Effect: A Meta-analysis.

Weinberger JM, Houman J, Caron AT, Patel DN, Baskin AS, Ackerman AL, Eilber KS, Anger JT.

Obstet Gynecol. 2018 Aug;132(2):453-458. doi: 10.1097/AOG.0000000000002733.

PMID:
29995725
4.

Effect Size in Efficacy Trials of Women With Decreased Sexual Desire.

Pyke RE, Clayton AH.

Sex Med Rev. 2018 Jul;6(3):358-366. doi: 10.1016/j.sxmr.2018.01.003. Epub 2018 Mar 22. Review.

PMID:
29576442
5.

Understanding the Role of Serotonin in Female Hypoactive Sexual Desire Disorder and Treatment Options.

Croft HA.

J Sex Med. 2017 Dec;14(12):1575-1584. doi: 10.1016/j.jsxm.2017.10.068. Review.

PMID:
29198512
6.

Sexual arousal: Sex matters.

Petherick A.

Nature. 2017 Oct 4;550(7674):S2-S3. doi: 10.1038/550S2a. No abstract available.

PMID:
28976951
7.

Flibanserin for hypoactive sexual desire disorder: place in therapy.

Gelman F, Atrio J.

Ther Adv Chronic Dis. 2017 Jan;8(1):16-25. doi: 10.1177/2040622316679933. Epub 2017 Jan 18. Review.

8.

Phase I Randomized Placebo-controlled, Double-blind Study of the Safety and Tolerability of Bremelanotide Coadministered With Ethanol in Healthy Male and Female Participants.

Clayton AH, Lucas J, DeRogatis LR, Jordan R.

Clin Ther. 2017 Mar;39(3):514-526.e14. doi: 10.1016/j.clinthera.2017.01.018. Epub 2017 Feb 9.

9.

Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide.

White WB, Myers MG, Jordan R, Lucas J.

J Hypertens. 2017 Apr;35(4):761-768. doi: 10.1097/HJH.0000000000001221.

10.

Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial.

Clayton AH, Althof SE, Kingsberg S, DeRogatis LR, Kroll R, Goldstein I, Kaminetsky J, Spana C, Lucas J, Jordan R, Portman DJ.

Womens Health (Lond). 2016 Jun;12(3):325-37. doi: 10.2217/whe-2016-0018. Epub 2016 May 16.

12.
13.

Melanotan II injection resulting in systemic toxicity and rhabdomyolysis.

Nelson ME, Bryant SM, Aks SE.

Clin Toxicol (Phila). 2012 Dec;50(10):1169-73. doi: 10.3109/15563650.2012.740637. Epub 2012 Nov 5.

PMID:
23121206
14.

Central nervous system agents and erectile dysfunction.

Kumar R, Nehra A.

Urol Clin North Am. 2011 May;38(2):165-73. doi: 10.1016/j.ucl.2011.03.006. Review.

PMID:
21621083
15.

Pharmacological profiling of neuropeptides on rabbit vaginal wall and vaginal artery smooth muscle in vitro.

Aughton KL, Hamilton-Smith K, Gupta J, Morton JS, Wayman CP, Jackson VM.

Br J Pharmacol. 2008 Sep;155(2):236-43. doi: 10.1038/bjp.2008.253. Epub 2008 Jun 30.

16.

Clinical applications of centrally acting agents in male sexual dysfunction.

Hellstrom WJ.

Int J Impot Res. 2008 Jul;20 Suppl 1:S17-23. doi: 10.1038/ijir.2008.18. Review.

PMID:
18552830
17.

Preclinical effects of melanocortins in male sexual dysfunction.

Shadiack AM, Althof S.

Int J Impot Res. 2008 Jul;20 Suppl 1:S11-6. doi: 10.1038/ijir.2008.17. Review.

PMID:
18552829
18.

Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study.

Safarinejad MR, Hosseini SY.

J Urol. 2008 Mar;179(3):1066-71. doi: 10.1016/j.juro.2007.10.063. Epub 2008 Jan 18.

PMID:
18206919
20.

Central nervous system-acting agents and the treatment of erectile and sexual dysfunction.

Carson CC 3rd.

Curr Urol Rep. 2007 Nov;8(6):472-6. Review.

PMID:
18042327

Supplemental Content

Loading ...
Support Center